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Abstract
Background: The metalloprotease meprin β cleaves the Alzheimer’s Disease (AD) relevant amyloid precursor
protein (APP) as a β-secretase reminiscent of BACE-1, however, predominantly generating N-terminally truncated
Aβ2-x variants.
Results: Herein, we observed increased endogenous sAPPα levels in the brains of meprin β knock-out (ko) mice
compared to wild-type controls. We further analyzed the cellular interaction of APP and meprin β and found that
cleavage of APP by meprin β occurs prior to endocytosis. The N-terminally truncated Aβ2-40 variant shows increased
aggregation propensity compared to Aβ1-40 and acts even as a seed for Aβ1-40 aggregation. Additionally, we
observed that different APP mutants affect the catalytic properties of meprin β and that, interestingly, meprin β is
unable to generate N-terminally truncated Aβ peptides from Swedish mutant APP (APPswe).
Conclusion: Concluding, we propose that meprin β may be involved in the generation of N-terminally truncated Aβ2-
x peptides of APP, but acts independently from BACE-1.
Keywords: Alzheimer’s Disease, Meprin β, Metalloprotease, Amyloid precursor protein, Amyloid β, N-terminal
truncation, APP mutations, Protein-protein interaction, Cell surface protein
Background
One of the major hallmarks of Alzheimer’s Disease (AD)
is the accumulation of soluble and aggregated amyloid β
(Aβ) peptides in the brains of AD patients. Aβ peptides
are generated from the amyloid precursor protein (APP)
in the amyloidogenic pathway through two consecutive
cleavage events. Most prominent, BACE-1 (β-site APP
cleaving enzyme 1) cleaves APP at the β-secretase cleav-
age site and generates the N-terminus of Aβ (described
in [1]). As an aspartyl protease, BACE-1 is responsible
for the majority of Aβ peptides generated in the acidic
environment of endosomes and lysosomes [2–5].
Second, the γ-secretase complex cleaves the remaining
99 amino acids long C-terminal fragment (CTF/C99)
and releases the C-terminus of Aβ. As both secretases
are not restricted to a single site, Aβ peptides vary in
length. BACE-1 can generate Aβ starting in position p1
or p11 (Aβ1-x/11-x) [3] whereas γ-secretase complex
has several cleavage sites and can generate varying C-
termini of Aβ [6–10]. Based on genetic evidence and
BACE-1 knock-out studies it has been demonstrated
that BACE-1 is the quantitatively most important en-
zyme to generate Aβ in mice overexpressing APP with
the Swedish mutation (APPswe), which is associated
with a distinct form of familial AD (FAD) [3, 11–15].
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However, N-terminally truncated Aβ variants starting
with the alanine in p2 (Aβ2-x), which cannot be attrib-
uted to BACE-1 activity, have also been described in AD
patients [16–19]. We recently identified meprin β as a
new enzyme in APP processing as it is able to generate
Aβ peptides starting with aspartate in p1 and with ala-
nine in p2 independent of BACE-1 activity [20, 21].
Meprin β, a type I transmembrane metalloprotease, has
biological functions in inflammation and collagen assem-
bly and is associated with diseases, such as inflammatory
bowel disease and fibrosis (reviewed in [22, 23]).
Although BACE-1 acts as the major β-secretase in vivo
generating most of the Aβ peptides at position 1, we
suggest that meprin β may act as an alternative enzyme
responsible for the release of small amounts of N-
terminally truncated Aβ species.
The relevance of the protease for APP processing is
further highlighted by its activity on endogenous APP in
the mouse brain. Additionally we demonstrate that
meprin β cleavage of APP occurs prior to the endocytic
compartments, as diminished APP endocytosis has no
influence on meprin β mediated Aβ generation (summa-
rized in Fig. 1). Moreover, we are able to demonstrate
that meprin β generates N-terminally truncated Aβ2-40/
42 peptides that display increased aggregation compared
to non-truncated Aβ peptides. This catalytic activity of
meprin β is differentially affected by mutated forms of
APP and in contrast to wt APP, meprin β is not able to
cleave APPswe at position 672 and does not generate N-
terminally truncated forms of Aβ from this APP mutant.
Results
A knock-out of meprin β leads to increased sAPPα secretion
in cortical neurons
We have previously shown that meprin β is able to cleave
APP and to generate Aβ peptides in vitro [20, 21, 24]. We
now wanted to elucidate the physiological role of meprin
β in APP processing in vivo. Therefore, we analyzed
endogenous APP processing in the brains of meprin β ko
(n = 6) mice compared to age-matched wt animals (n = 6).
Endogenous sAPPα and sAPPβ were detected in the
soluble fractions and full-length APP was detected in
membrane fractions of brain lysates (Additional file 1).
Levels of endogenous full-length APP remained identical
(Fig. 2a), but the release of endogenous sAPPα was in-
creased in meprin β ko mice (Fig. 2a, b). This suggests that
there might be more APP substrate for ADAMs in the ab-
sence of meprin β and supports the involvement of en-
dogenous meprin β in APP processing in vivo (Additional
file 2). The levels of sAPPβ were also slightly increased in
meprin β ko mice (Fig. 2a, c), but note, that the sAPPβ
specific antibody (192wt, Fig. 1) recognizes only the neo
C-terminus of sAPPβ after BACE-1 (or minor meprin β)
cleavage between M671/D672 and is therefore not able to
Fig. 1 Schematic representation of the proteolytic cleavage of APP by meprin β. We found molecular interaction of APP and the metalloprotease
meprin β in the secretory pathway and at the cell surface. On the right site, specific antibodies for APP/APP fragments and their epitopes are marked.
Note that the neo-epitope 192wt antibody only recognizes “full-length” sAPPβ having methionine at the C-terminus, while the shorter sAPPβ starting
with lysine produced via meprin β cleavage cannot be detected
Schönherr et al. Molecular Neurodegeneration  (2016) 11:19 Page 2 of 16
detect the longer sAPPβ form generated by meprin β
cleavage between D672 and A673. Overall, these findings
demonstrate that meprin β affects endogenous APP pro-
cessing in the mouse brain.
Decrease of Aβ2-40 and increase of mature APP in primary
neurons of meprin β knock-out mice
Since we detected differences in sAPPα levels for wt
versus meprin β ko mice, we focused on total en-
dogenous Aβ in supernatants of primary cortical
neurons. Via ELISA assay we could show that total
Aβ40 levels showed a trend to decrease (by about
13 %) in meprin β ko neurons (n = 6) compared to
controls (n = 6) (Fig. 2d); however due to the antibody
specificity we were unable to detect any endogenous
mouse Aβ2-40. To circumvent this problem, we ana-
lysed N-terminally truncated Aβ variants and precipi-
tated Aβ of supernatants of primary cortical neurons
of the same mice infected with a recombinant adeno-
virus expressing APP695. We precipitated Aβ from
cell supernatants 48 h post infection with subsequent
separation on 8 M urea gels. We detected a decrease
of Aβ2-40 levels in meprin β ko neurons compared
to wt of about 50 % (Fig. 2e, f ). Moreover, we ob-
served an increase in levels of mature APP in neu-
rons of meprin β ko mice compared to wt controls
(Fig. 2e), indicating processing of fully glycosylated
APP after posttranslational modification by meprin β.
BACE-1 activity is not increased by meprin β
preincubation
We have previously shown that generation of Aβ2-40 by
meprin β in vitro is independent of BACE-1 [21]. How-
ever, since levels of sAPPα are increased in meprin β ko
mice, we wanted to clarify if meprin β is capable of regu-
lating BACE-1 activity directly. Close to the proposed
activation site in the propeptide of BACE-1 a patch of
negatively charged amino acids is found. Meprin β is
known to prefer aspartate and glutamate residues
around the cleavage site [24] and thus we performed a
BACE-1 activity assay to test the potential role of meprin
β acting as an activator of BACE-1 by cleaving off the
propeptide (Fig. 3). We incubated C-terminally
truncated soluble recombinant proBACE-1 with active
meprin β and measured BACE-1 activity using a
quenched fluorogenic peptide (mca-VNLDAE-dnp)
comprising the sweAPP cleavage site. BACE-1 activity at
acidic pH was not increased after meprin β preincuba-
tion, indicating that there is no activity stimulating effect
mediated by meprin β (Fig. 3a, b). Meprin β activity at
pH 7.5 was measured as control (Fig. 3c).
Co-immunoprecipitation reveals interaction of APP and
meprin β
We have recently shown that APP is a substrate of the
metalloprotease meprin β, even in BACE-1 knock-out
cells [21]. However, in contrast to BACE-1 mediated
Fig. 2 Increased sAPPα levels in meprin β ko mice. a-c Soluble and membrane fractions of brain lysates from meprin β ko (Mep1b−/−) (n = 6) and wt
(n = 6) mice were probed with antibodies specific for sAPPα (7A6), sAPPβ (192wt) (Additional file 1), full-length APP (22C11) and actin or tubulin as
loading controls (note that only representative n = 3 for each is shown). b Note that endogenous sAPPα levels were increased in the absence of
meprin β, indicating a changed APP processing profile in Mep1b−/− compared to wt mice. d Aβ40 levels of supernatants of primary cor-
tical neurons of wt (n = 3) and meprin ko mice (n = 6) were detected via Meso Scale ELISA using sulfo-tagged 4G8 antibody. Meprin β ko
mice showed approximately 13 % less Aβ40 (normalized to total protein of lysates). e Urea gel of immunoprecipitated Aβ (using IC16
antibody) of supernatants of primary cortical neurons of wt and meprin β ko mice infected with a recombinant adenovirus expressing
APP695. Lysates showed a decrease in mature APP for meprin β ko (CT15 antibody). f Quantification of Aβ2-40 levels (normalized to
tubulin of lysates) of (e) showed a decrease of approximately 50 % in meprin β ko neurons (n = 2)
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cleavage of APP, nothing was known about the cellu-
lar localization of meprin β and APP interaction. To
strengthen the involvement of meprin β in APP pro-
cessing, we first explored whether APP and meprin β
directly interact. We could show for the first time co-
immunoprecipitation of myc-tagged APP and meprin
β with the 9E10 antibody (anti-myc) from lysates of
HEK-293 T cells transiently co-transfected with
meprin β and APP695myc (Fig. 4a). We could clearly
observe an effect of meprin β on APP processing in
the lysate input control since levels of mature APP
were decreased in co-transfected cells. Likewise, in a
reverse experiment MEP1B antibody (anti-meprin β)
co-precipitated transfected full length APP. Control
experiments in which cells were single-transfected
with APP (“L1”) or meprin β (“L2”) with subsequent
mixing of the cellular lysates (Mix) confirmed that
immunoprecipitation with 9E10 or the meprin β anti-
body only pulled either APP or meprin β showing
that the interaction of APP and meprin β occurred
only in the living cells and that APP and meprin β
specifically interacted only in co-transfected cells.
APP and meprin β co-localize in the late secretory pathway
or at the cell membrane
To further analyse the cellular localization of the APP/
meprin β interaction and meprin β enzymatic activity on
APP processing, we used a well-established APP con-
struct lacking the C-terminal motif NPxY (APPΔNPxY),
which is critical for proper endocytosis [2]. Using this
construct allowed us to investigate APP processing prior
to the endocytic compartment, hence prior to the
BACE-1 mediated Aβ generation. We performed a sur-
face staining of MEF cells, transiently overexpressing
meprin β and APPΔNPxY. To visualize only surface lo-
calized proteins we directly incubated the cells with
anti-Aβ IC16 antibody [25] and anti-meprin β antibody
after fixation and blocking without permeabilization to
ensure that antibodies do not penetrate into the cell.
The confocal images nicely show a co-localization of
Fig. 3 BACE-1 activity is not influenced by meprin β. a, b Proteolytic activity of recombinant BACE-1 or recombinant meprin β was measured at
pH 4.0 using a quenched fluorogenic peptide comprising the β-site sequence of APP Swedish mutant. BACE-1 activity was inhibited using a
specific inhibitor (Inh IV, Calbiochem). Preincubation of BACE-1, a mixture of 50 % mature and 50 % zymogen enzyme (R&D Systems), with meprin
β revealed no additional increase in BACE-1 activity (b). c As control meprin β activity was additionally measured at pH 7.5
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Fig. 4 (See legend on next page.)
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both proteins at the cell surface (Fig. 4b). As expected,
our untransfected negative control and the controls of
transfected cells that were only incubated with the cor-
responding secondary antibody, did not show any sur-
face staining (data not shown).
To further highlight the colocalization of APP with
meprin β, we co-transfected HEK cells with APP and
meprin β constructs that are tagged with a fragment of
the green fluorescent protein (GFP) (APP-GFP11, only
bearing barrel 11 of GFP; meprin β-GFP1-10, only bear-
ing barrel 1–10). Neither the GFP11 fragment nor the
GFP1-10 fragment alone showed any fluorescence. How-
ever, when both fragments are in close proximity, the
function of an intact GFP is regained and it is emitting
fluorescence. Thus, fluorescence in cells co-transfected
with APP-GFP11 and meprin β-GFP1-10 indicates a
colocalization of both proteins. Of note, colocalization
was mostly found in the secretory pathway within the
cis-golgi compartment (GM130 antibody) (Fig. 4d), there
was lesser colocalization within the ER (PDI) (Fig. 4c),
however hardly any in early endosomes (EEA1) (Fig. 4e).
We further validated the specificity of this proposed
colocalization using immunocytochemical stainings with
organelle markers of fixed HEK cells tranfected with
APP-GFP and meprin β-dsRed (Additional file 3).
To elucidate a potential APP processing by meprin
β at the cell surface, we transfected APP695wt or
APPΔNPxY with or without meprin β into HEK-
293 T cells and performed a cell surface biotinylation
assay (Fig. 4f ). The mature form of APP is cleaved by
meprin β and is therefore reduced in cell lysates and
at the cell surface. Surface APP695wt is almost com-
pletely cleaved and thus significantly reduced by 70 %
when meprin β is also present at the cell surface
(Fig. 4g). Surface APPΔNPxY is even stronger reduced
by meprin β by 85 % when internalization is
impaired. We further analyzed Aβ variants derived
from these cells using 8 M urea SDS-Page. We could
observe that an increased generation of Aβ1-40, Aβ2-
40 and Aβ2-42 peptides by meprin β is not
dependent on internalization. Furthermore, to prove a
direct involvement of meprin β in Aβ generation we
inhibited BACE-1 activity using different BACE-1 in-
hibitors like a BACE-1 tripartite inhibitor (described
in [26]) or BACE-1 IV inhibitor (data not shown). In-
hibition of BACE-1 activity did not alter the Aβ pat-
tern generated by meprin β, but decreased levels of
Aβ1-40 in cells lacking meprin β overexpression,
which indicates the potency of the inhibitor (Fig. 4h).
This suggests that meprin β cleaves APP and gener-
ates Aβ2-40/42 prior to the endocytic compartments
as APPΔNPxY proteins remain at the cell surface and
seem to serve as more accessible substrates for
meprin β.
Meprin β generated Aβ2-40 promotes and seeds
aggregation of Aβ peptides
As meprin β generates Aβ2-40 and Aβ2-42 and since
N-terminally truncated Aβ variants can be found in
the CSF and senile plaques of AD patients [16], we
were interested in the aggregation of the truncated
and non-truncated (wt) Aβ variants. Therefore, we
compared the aggregation of truncated Aβ2-40 and
the non-truncated Aβ1-40 variant. Aggregation was
monitored by measuring the Thioflavin T (ThT) fluor-
escence upon binding to Aβ aggregates (Fig. 5a). Both
truncated Aβ2-40 and non-truncated Aβ1-40 variants
showed characteristic sigmoidal aggregation curves.
Interestingly, truncated Aβ2-40 peptide showed sig-
nificantly faster aggregation as compared to non-
truncated Aβ1-40 peptide. The truncated Aβ2-40 pep-
tide had a shorter lag phase of about ~12.5 min as
(See figure on previous page.)
Fig. 4 Cellular interaction between meprin β and APP occurs prior to endocytosis. a APP695myc and meprin β were overexpressed in HEK-293 T
cells. Total lysates were immunoprecipitated with 9E10 (for APP) or anti-meprin β antibody. Co-purified proteins were detected using antibodies
as indicated (WB: 9E10 for APP and reciprocal WB: meprin β). 20 μg of each lysate was used as transfection control (lysate input). As control,
lysates of cells separately expressing either APP (“L1”) or meprin β (“L2”), were mixed post-lysis (lanes “Mix L1 + L2”). Co-purified proteins were
immunoblotted as indicated. APP and meprin β specifically interacted only in co-transfected cells, but not post-lysis. b MEF cells were transiently
co-transfected with APP695ΔNPxY and meprin β. Surface staining was performed, using IC16 antibody for detection of APP and an anti-meprin β
antibody. Secondary antibodies Alexa-Fluor546 and Alexa-Fluor488 were used, respectively. The confocal image shows colocalization of APP (red)
and meprin β (green). Single channels are depicted aside. The right image shows the cell morphology as bright-field picture (Scale bar: 10 nm).
(C,D,E) GFP fluorescence shows colocalizing APP and meprin β (depicted in green) (Scale bar: 10 nm). c Only little colocalization of APP and
meprin β can be found in the endoplasmic reticulum (PDI; depicted in red). d Colocalization was mostly found within the cis-golgi compartment
(GM130; depicted in red). e Colocalization in early endosomes was hardly detectable (EEA1; depicted in red). f, g HEK-293 T cells were transiently
co-transfected with APP695wt or APPΔNPxY, and meprin β or empty vector. Detection of proteins was carried out using specific antibodies. f
24 h post transfection, surface proteins were labeled using sulfo-NHS-LC-LC biotin and precipitated with NeutrAvidin agarose beads. g Quantifica-
tion of biotinylated surface APP (graph shows mean ± S.E. (n = 3); statistical significance: * < 0.05, ***p < 0.001; t-test). h Aβ variants of conditioned
medium was immunoprecipitated using IC16-conjugated dynabeads and separated on 8 M urea SDS-Page. Alternatively, cells were treated over-
night with 100 nM tripartite BACE-1 inhibitor [26]. Samples were run on one gel, but rearranged for better presentation. Shown is one representa-
tive of six independent experiments. Generation of Aβ variants by meprin β was preserved in endocytosis impaired APPΔNPxY, indicating that
cleavage occurred on the way to or at the cell surface
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compared to that of non-truncated Aβ1-40 of
~100 min. In addition, truncated Aβ2-40 also showed
an increased elongation rate reaching a higher aggre-
gation level than the Aβ1-40 peptide. A decay in ThT
fluorescence was observed with Aβ2-40 peptide simi-
lar to the previously reported N-terminal truncated
Aβ4-x peptide, probably due to the masking of ThT-
binding sites within higher order aggregates or
clumps [27]. These data indicate that the aggregation
of N-terminally truncated Aβ2-40 peptide is signifi-
cantly different from that of the non-truncated wt
Aβ1-40 peptide. In particular, the Aβ2-40 species ag-
gregate faster and reached a higher aggregation state
than Aβ1-40 peptide.
We also investigated the seeding potency of the
truncated Aβ2-40 variant. In a nucleation-dependent
aggregation assay, we studied the effect of truncated
Aβ variants on the aggregation of the non-truncated
Aβ variant. Preformed oligomeric nuclei of truncated
Aβ2-40 peptide significantly reduced the lag period of
fibrillization (Fig. 5b). While Aβ1-40 alone showed a
characteristic lag phase (~125 min.), preformed oligo-
meric nuclei of truncated Aβ2-40 strongly shortened
the lag phase to ~60 min. Altogether, these data dem-
onstrate that the truncated Aβ2-40 aggregates rapidly,
and also could efficiently seed the aggregation of
non-truncated (wt) Aβ variants.
The “protective” APP A673T mutation is less prone to
cleavage by meprin β
A recently described APP mutation in position 673
(A673T) has been shown to protect against AD as well
as against cognitive decline in the elderly independently
of AD [28–30]. This mutation is located adjacent to the
β-secretase cleavage site in the Aβ sequence at p2 and
reduces Aβ generation by 40 % in vitro. [28]. According
to the findings reported above we speculated that this
amino acid exchange (A673T) may also influence the af-
finity of meprin β towards APP. To investigate the influ-
ence of this mutation on meprin β cleavage of APP, we
performed a cleavage assay using recombinant enzyme
and synthetic peptides including the A673T mutation.
HPLC and subsequent MALDI analysis revealed pre-
ferred cleavage of the wt over the A673T APP peptide
by meprin β (Fig. 6a, b; Additional file 4). Indeed,
meprin β prefers alanine over threonine in P1’ position
[24], which may explain reduced cleavage of APP A673T
by meprin β.
To further clarify Aβ generation by meprin β from
APP A673T in vitro, we compared Aβ variants generated
Fig. 5 Aβ2-40 shows increased aggregation propensity and could seed the aggregation of non-truncated Aβ. Aggregation of synthetic Aβ
peptide (truncated Aβ2-40 and non-truncated Aβ1-40) variants were monitored by Thioflavin T (ThT) fluorescence assay during incubation at 37
°C for 24 h (a). The aggregation assay was performed in 50 mM sodium phosphate buffer and a final Aβ concentration of 50 μM. The truncated
Aβ2-40 peptide demonstrate a shorter lag phase and rapid aggregation behavior as compared to non-truncated Aβ1-40 variant. b Demonstration
of the seeding capacity of Aβ2-40 peptides. Aggregation of Aβ1-40 with and without preformed oligomeric nuclei of Aβ2-40 was monitored by
ThT fluorescence assay. Initial aggregate formation is accelerated by the addition of the Aβ2-40 seeds, as indicated by the reduced lag phase. The
graphs on the right-side in (a) and (b) display the same results with extended time scale to demonstrate the differences in the lag phase.
The differences are statistically significant. For Unpaired t test and F test, the P value is < 0.0001
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of APPwt or APP A673T by meprin β (Fig. 6c). In APP
A673T transfected cells we observed no change in Aβ1-40
levels compared to those of APPwt. Furthermore, we de-
tected a distinct signal below the Aβ1-40 band, which
could not be attributed to one of the Aβ marker peptides.
However, we suggest that this band is also representing
Aβ2-40 (Additional file 5), but starting with a threonine at
position two and shifted due to changes in hydrophobicity.
Therefore, we compared the Aβ2-40/1-40 ratio of APP695
wt and A673T mutant co-transfected with meprin β
(Fig. 6d). Our analysis revealed a significant decrease of
~70 % in the Aβ2-40/1-40 ratio in the A673T mutant due
to reduced Aβ2-40 production (Fig. 6d).
APPswe mutation affects meprin β cleavage
We have recently shown that meprin β overexpression re-
sults in increased levels of Aβ2-40. Therefore, we decided
to use the Aβ2-40/1-40 ratio as a measure for meprin β ac-
tivity. In contrast to BACE-1, meprin β exhibits the same
increased affinity for APPwt peptides and those carrying
the Swedish mutation (K670N/M671L) in vitro [21]. How-
ever, here we demonstrate that generation of the N-
terminally truncated Aβ2-40/42 variants by meprin β from
APP carrying the Swedish FAD mutation (APPswe) was al-
most completely abolished compared to APPwt controls
(Fig. 7a, b). To analyse whether other FAD mutations may
affect meprin β activity in a similar fashion or whether only
mutations localized closely to the N-terminus of the Aβ
sequence influence meprin β cleavage specificity, we also
investigated the FAD causing London APP mutation
(APPlon, V717I). Using APPlon we observed that the ratio
of Aβ generation in meprin β co-expressing cells is compar-
able to APPwt, indicating that changes close to the N-
terminal sequence of the Aβ region may directly affect
meprin β cleavage specificity. Additionally, we tested the
Swedish/London double mutation and could not detect a
signal for Aβ2-40 which can be therefore attributed to the
APPswe mutation. To further support this, we employed
data from a previously performed peptide cleavage assay
[24], and analyzed with the help of a web-based tool [31], if
the change of methionine (APPwt) to leucine (APPswe) al-
ters the preference of meprin β for certain amino acid resi-
dues around the cleavage site (Fig. 7c, d). Indeed, while
aspartate in P1 position (nomenclature by Schechter & Ber-
ger [32]) is highly preferred in APPwt, this residue is clearly
disliked at this particular position when leucine is set in P2,
explaining the loss of Aβ2-40/42 generation by meprin β in
APPswe.
Overall, we could clearly show that the amino acid
composition around the β-site in APP affect meprin β
cleavage preference. This is most striking for APPswe,
which completely abolished Aβ2-40 generation.
Discussion
The proteolytic cleavage of the amyloid precursor pro-
tein and the accumulation of Aβ peptides in the brain
Fig. 6 The “protective” APP A673T mutation decreases cleavage by meprin β. a, b 15 nM recombinant meprin β was incubated with synthetic
APP peptides at 37 °C. HPLC analysis showed that processing kinetics of APP A673T were decreased (b) compared to wt APP (a) (see also
Additional file 4). c Supernatants of HEK-293 T cells, transiently transfected with APPwt or APP A673T mutant and co-transfected with meprin β or
empty vector were immunoprecipitated with anti-Aβ 6E10-Dynabeads, subsequently separated on an 8 M urea gel and probed with 6E10. The
Aβ2-40 band, visible in samples transfected with APPwt and meprin β, is slightly shifted in samples transfected with APP A673T and meprin β. All
samples were run on one gel but rearranged for better presentation. d A significant decrease of the Aβ2-40/1-40 ratio was observed in culture
supernatants of cells co-transfected with APP A673T and meprin β compared to cells co-transfected with APPwt and meprin β (graph shows
mean ± SEM (n = 5); statistical significance: *, p = 0.0317; t-test)
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are key events in the pathogenesis of AD [10, 33]. It was
shown that the deletion of BACE-1 in transgenic mice
overexpressing APPswe abolishes Aβ generation in the
brain [15, 34–36] and rescues behavioral and
electrophysiological deficits [34, 37]. However, several
N-terminally truncated Aβ variants have also been de-
scribed in the CSF and brains of AD patients and cannot
be attributed to BACE-1 activity [1, 16–19, 38–40]. This
suggests that proteases other than BACE-1 may be in-
volved in the generation of N-terminally truncated Aβ
peptides in the brain. Since we could already show that
the metalloprotease meprin β generates N-terminally
truncated Aβ peptides in vitro [21] we propose that it
may be a candidate for this cleavage event. We already
showed a different APP cleavage pattern in brains of
meprin β ko compared to wt mice, suggesting that
meprin β is involved in N-terminal processing of en-
dogenous APP in vivo [20]. In this study, we observed
increased levels of endogenous sAPPα in meprin β ko
mice. sAPPα is generated through cleavage at the α-
secretase cleavage site within the Aβ sequence by
ADAM10 [41–46]. A similar increase in sAPPα levels
has been observed in BACE-1 ko mice or after treatment
of mice with BACE-1 inhibitors [35, 47, 48]. We specu-
late that due to the absence of meprin β more substrate
is available for ADAM10 cleavage. Since the 192wt anti-
body does only recognize the shorter sAPPβ variant
mainly produced by BACE-1cleavage, it does not reflect
the total sAPPβ load (Fig. 1). Therefore, we can see an in-
crease of this variant in meprin β ko mice, since more sub-
strate is available for BACE-1. Additionally, we detected a
decrease of approximately 13 % of endogenous Aβ40
levels in meprin β ko neurons compared to wt controls.
To gain further insights into Aβ production of endogen-
ous meprin β we infected primary meprin β ko and wild-
type control neurons with recombinant adenovirus ex-
pressing human APP695. These showed a decrease of ap-
proximately 50 % of Aβ2-40 levels compared to wt
neurons. The remaining Aβ2-40, which is also present in
the ko, may be explained by other proteolytic events like
N-terminal truncation of the full-length Aβ originally gen-
erated by BACE-1, through aminopeptidases like APA
Fig. 7 Meprin β cleavage is affected by mutations in APP. a, b Western Blots of 8 M urea gels showed a distinct Aβ2-40 band in HEK-293 T cells
transiently co-transfected with APP695wt or APPlon and meprin β. Supernatants were immunoprecipitated for Aβ using 6E10 antibody. Note that
APPswe or APPswe/lon transfected cells, co-transfected with meprin β, did not show the Aβ2-40 band (graph shows mean ± SEM (n = 4); statistical
significance: * < 0.05; t-test). c, d Subsite cooperativity determines the meprin β cleavage site in APP. Previously identified meprin β cleavage sites in
peptides derived from HEK-293 T cell lysates [24] were analyzed by a web-based tool [31] to visualize changes in the preference for certain amino acid
residue around the scissile bond (black line). Green color indicate high, red color low preference. Aspartate in P1 position is well preferred in APPwt,
but disliked in APPswe
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[49]. We further wanted to elucidate whether there are
other possible explanations for an increase of β-site cleav-
age in meprin β wt versus ko mice, like an activation of
BACE1 via meprin β. The propeptide of BACE-1 is
cleaved off by furin or other proprotein convertases within
the secretory pathway [50]. Interestingly, Creemers and
colleagues showed that there is β-secretase activity to-
wards APP which is not influenced by the presence of the
propeptide. However, to exclude a potential role of meprin
β as BACE-1 cleaving and thus activating enzyme, we per-
formed an activity assay. Our results illustrate that meprin
β has no effect on BACE-1 activity under pH conditions
of active BACE-1.
As the interaction of BACE1 with APP at the cell
surface and in early endosomes has been demon-
strated [51, 52], we were therefore interested whether
we could detect a direct interaction of the metallo-
protease meprin β and its substrate APP. To further
elucidate in which cellular compartment meprin β
mediated Aβ generation occurs, we used an APP con-
struct with impaired endocytosis due to a deletion of
the tyrosine dependent sorting signal (NPxY motif;
ΔNPxY) at the C-terminus [2, 53]. Since APP is
endocytosed, most of the Aβ1-40/1-42 generation and
BACE-1 activity is found in endosomes due to its
acidic pH optimum as an aspartyl protease [3–5].
Meprin β, however, belongs to the astacin family of
zinc endopeptidases and is mainly active at or near
the cell surface as a membrane-bound enzyme. Re-
cently we could show that a hyperactive mutant of
meprin β, which was exclusively localized at the
secretory pathway and not secreted, resulted in en-
hanced APP shedding and Aβ generation [54]. Add-
itionally, rat meprin β was shown to exhibit an acidic
pH optimum with additional proteolytic activity at
basic pH [55]. Therefore, it is possible that meprin β
cleaves APP in the late secretory pathway, at the cell
surface or – like BACE-1 – in endosomes. To exclude
the endosomal pathway for meprin β, we used
APPΔNPxY, which allows to normal post translational
modification, maturation and transport to the cell
surface. However, internalization and degradation of
APPΔNPxY is impaired and thus BACE-1 mediated
Aβ generation is strongly reduced [2, 56, 57]. We an-
alyzed the processing of full-length APP and the gen-
eration of N-terminally truncated Aβ in cells co-
expressing APPΔNPxY and meprin β. Mature surface
APP almost completely vanished through cleavage of
meprin β and this effect was even greater when endo-
cytosis of APP was impaired. In contrast to BACE-1,
meprin β was still able to cleave APP and to generate
N-terminally truncated Aβ peptides when internaliza-
tion of APP is decreased. Thus, our results demon-
strate a spatial segregation of APP cleavage by meprin
β from BACE-1 mediated APP cleavage. We
hypothesize that still most of the initial APP process-
ing of the amyloidogenic pathway occurs in the endo-
somal compartment by BACE-1, but that the N-
terminally truncated Aβ2-40 and Aβ2-42 variants are
generated at or close to the cell surface by meprin β.
Our immunofluorescence data using the split-GFP
assay combined with antibody stainings against trans-
fected proteins further support these results, since we
could detect meprin β and APP/APP ΔNPxY in close
proximity prior to internalization. Moreover, a recent
study described that a hyperactive mutant of meprin
β led to massive shedding of APP already within the
secretory pathway, again pointing to a potential inter-
action of the two proteins before endocytosis [54].
Some studies suggest that N-terminally truncated
Aβ peptides may act as seeds and promote the aggre-
gation of Aβ1-40 peptides with detrimental effects. So
far, many studies have examined the characteristics of
Aβ3-x, which can be N-terminally cyclized to pyroglu-
tamate Aβ (pEAβ3-x) [39, 58–61], Aβ4-x [1, 27, 62] and
Aβ5-x [38, 40, 63]. We have found meprin β mediated
generation of Aβ2-x and therefore analyzed its aggregation
and nucleation propensities. Indeed, Aβ2-40 has a high
tendency to form aggregates compared to Aβ1-40. Fur-
thermore, we studied the effects of an Aβ variant with
high aggregation propensity over a variant with only low
and could show that Aβ2-40 peptide nucleates the aggre-
gation of Aβ1-40 in a dose-dependent manner. To our
knowledge, this is the first study characterizing Aβ2-40
showing that it has a high aggregation propensity and nu-
cleates the aggregation of non-truncated Aβ1-40 peptides
in vitro.
Since several mutations within the APP sequence have
been shown to have an impact on BACE-1 cleavage af-
finity on APP, we analyzed a recently described APP mu-
tation A673T that has been shown to protect against
AD as well as against cognitive decline in the elderly in-
dependent of AD. The mutation lies at position two of
Aβ (Aβ-A/T) and has been shown to reduce BACE-1
mediated Aβ generation by 40 % using synthetic
peptides as substrates [28]. Moreover, a significantly
decreased Aβ production in human APP A673T-
overexpressing primary neurons has been observed [30,
64]. Additionally, a decreased aggregation propensity of
Aβ-A/T could be measured, which is showing the com-
plexity of the protective effects of the substitution. Thus,
we analyzed meprin β mediated cleavage of APP A673T
in cell culture and in a peptide cleavage assay and re-
vealed a significant decrease of ~70 % in the Aβ2-40/1-
40 ratio compared to wt APP. This is consistent with the
data of our cleavage assay which focused on the cleavage
preference of meprin β by using recombinant enzyme
and synthetic peptides including the mutation and
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analysis via HPLC and subsequent MALDI. Here, we de-
tected the preference of alanine over threonine in P1’
position [24]. Surprisingly, we observed that Aβ2-x vari-
ants were missing in cells overexpressing meprin β and
APP bearing the Swedish double mutation K670N/
M671L (APPswe) which is located in close vicinity of the
β-secretase cleavage site. Here, we found a significantly
reduced meprin β mediated Aβ2-40/42 generation. Al-
though BACE-1 is clearly the most prominent enzyme
responsible for the generation of Aβ1-40 and Aβ1-42
peptides from the APPwt or APPswe sequences, we
propose, that meprin β may be responsible for generat-
ing small amounts of N-terminal truncated Aβ2-40 and
Aβ2-42 peptides almost exclusively from the APPwt se-
quences. This clearly shows a significant influence of
amino acid substitutions around the β-secretase cleavage
site for meprin β mediated Aβ generation. We suggest
that the amino acid substitution close to the meprin β
cleavage site provides a mechanistic explanation for the
differential generation of truncated Aβ species from
APPwt versus APPswe constructs.
Conclusion
Concluding, we observed increased endogenous sAPPα
levels in the brains of meprin β knock-out (ko) mice
compared to wild-type controls. Moreover, we could
show an interaction of APP and meprin β by co-
immunoprecipitation in overexpressing cells. Further-
more, we could demonstrate that, besides BACE-1,
which is by far the most important secretase responsible
for the generation of Aβ, meprin β could be a subsidiary
candidate protease in generating N-terminally truncated,
aggregation-prone Aβ2-x peptides that have been de-
scribed in AD patients. We also observed that the β-
secretase activity of meprin β depends on the amino acid
composition around the cleavage site in APP as demon-
strated for the APPswe sequence and the AD protective
mutant A673T. In particular, meprin β was incapable of
cleaving APPswe at position 672 and generating N-
terminally truncated Aβ from this mutant substrate.
Methods
Animals
Mature congenic Mep1β−/− mice on a C57Bl/6 back-
ground, as previously described [65], were maintained
on a 12-h light–dark cycle, with food and water ad libi-
tum. Control and Mep1β−/− animals were anesthetized
by sodium pentobarbital overdose and sacrificed by cer-
vical dislocation. Entire brains were removed and sub-
dissected into cerebellum, frontal cortex, temporal
cortex, hippocampus and “the rest” of the brain prior to
further analyses. All mice were kept under specific
pathogen-free conditions.
Mouse brain lysates
Meprin β ko (n = 6) and wt littermates (n = 6) were sacri-
ficed by decapitation. Snap frozen hemispheres were ho-
mogenized in 1 ml DEA buffer (50 mM NaCl, 2 mM
EDTA, 0.2 % diethylamine, protease inhibitors) and in-
soluble material was precipitated by centrifugation. DEA
fraction was ultracentrifuged at 100.000 x g for 30 min.
The resulting supernatant was retained as the soluble
fraction and neutralized by addition of 10 % 0.5 M Tris/
HCl, pH 6.8. The DEA insoluble material was homoge-
nized with 1 % Triton-X lysis buffer and cleared by
centrifugation [66]. Brain lysates were separated by SDS-
PAGE and subsequently probed using monoclonal anti-
body (mAb) 7A6 specific for sAPPα, polyclonal antibody
192 specific for sAPPβ, mAb 22C11 recognizing the
APP ectodomain, and actin for loading control [44]. For
co-immunoprecipitation, brains were homogenized in
lysis buffer (20 mM TrisHCl (pH 7.5), 150 mM NaCl,
0.5 % Triton X-100, protease inhibitors) [67].
Enzyme Linked Immunosorbent Assay
Samples were analysed by the Aβ Triplex Immunoassay
from Meso Scale Discovery using the sulfo-tagged 4G8
antibody for mouse Aβ detection. Aβ40 concentration
was calculated using the MSD Discovery Workbench
Software.
Cortical cultures and infection
Primary cortical neurons were obtained from prenatal
(E15) mice. Dissociated neurons were seeded at a density
of 63,000 cells/cm2 on polyornithin (Sigma) precoated
culture dishes and maintained in Neurobasal/B27 media
(Gibco) supplemented with Glutamax (Gibco). Cells
were infected with a recombinant adenovirus expressing
human APP695 at a concentration of 100 pfu/cell for
6 h in DIV1 as described [68].
BACE-1 activity assay
1 μg of C-terminally truncated recombinant proBACE1
(R&D systems) was incubated with 15 nM recombinant
active meprin β at pH 7.5. Afterwards, pH was changed
to pH 4.0 and BACE-1 activity was measured using a
quenched fluorogenic peptide (mca-VNLDAE-dnp)
comprising the sweAPP cleavage site. As control, BACE-
1 inhibitor IV (Calbiochem) was applied.
Cell culture, transient transfection and cell lysis
HEK-293 T cells were maintained and passaged in Dul-
becco’s Modified Eagle Serum (DMEM) supplemented
with 5 % fetal calf serum (FCS) and 0.5 % sodium pyru-
vate in an incubator at 37 °C and 5 % CO2. Transient
transfection of HEK-293 T cells was performed using
calcium-phosphate or FuGENE®HD (Promega). For all
transfections the vectors pLHCX or pLBCX were used.
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24 h post transfection, 293 T cells were lysed in NP-40
lysis buffer (500 mM Tris, pH 7.4, 150 mM NaCl, 5 mM
EDTA, 1 % (v/v) Nonidet P-40, 0.02 % (v/v) Sodium
Azide), plus Complete Protease Inhibitor Cocktail
(Roche) for 20 min at 4 °C on ice. Subsequently cell deb-
ris was pelleted by centrifugation at 20.000 x g for
20 min at 4 °C in a microcentrifuge. Protein content of
cleared lysates was determined by BCA assay (Pierce
Chemicals, Rockford, IL, USA).
Co-immunoprecipitation of APP and meprin β
HEK-293 T cells were transiently co-transfected with
meprin β-pLBCX and APP695myc-pLHCX, or with either
meprin β or APP plus empty vector as control. 24 h post
transfection, 293 T cells were lysed in NP-40 lysis buffer
(500 mM Tris, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1 %
(v/v) Nonidet P-40, 0.02 % (v/v) Sodium Azide), plus
Complete Protease Inhibitor Cocktail (Roche) for 20 min
at 4 °C on ice. 20 μg of total cell lysates were used as input
control. For co-immunoprecipitation, equal amounts of
total lysates (200 μg) were incubated over night with 30 μl
of protein G sepharose beads (50 % (v/v) slurry) (GE
Healthcare), and either monoclonal 9E10 antibody for
myc-tagged APP at 1:20 dilution, or polyclonal anti-
meprin β antibody, MEP1B (R&D Systems) at 1:100 dilu-
tion. Beads were collected by low speed centrifugation and
washed three times with NP-40 lysis buffer. Bound pro-
teins were eluted from sepharose beads with 30 μl 2x SDS
sample buffer at 95 °C.
Split GFP cloning
The plasmid pcDNA3.1-APP695 CT split GFP11 was
used as template to subclone the APP695 CT split
GFP11 construct into a pLHCX backbone with a 5´Hin-
dIII and a 3´ClaI restriction site 31. We used the plas-
mid pcDNA3.1-APP695 CT split GFP11 as a template to
subclone meprin β CT split GFP1 10 with a 5´MluI und
3`ClaI restriction site into pLHCX.
Immunofluorescence microscopy
Murine embryonic fibroblasts (MEF) or HEK-293 T
cells were seeded on cover slides precoated with poly-
ornithin. For surface staining MEF cells were transi-
ently co-transfected with meprin β-pLBCX and
APP695ΔNPxYmyc-pLHCX. For compartment staining
HEK-293 T cells were transiently co-transfected with
pLHCX-APP695 CT split GFP11 and pLHCX-meprin
β CT split GFP1-10. 24 h post transfection, cells were
fixed with 4 % PFA for 10 min at room temperature
and, except MEF cells for the purpose of surface
staining, permeabilized in 0.5 % Triton X in PBS for
20 min . For surface staining cells were washed three
times with TBS before and after blocking in 4 % BSA.
Cells were incubated with IC16 antibody (1:300),
recognizing residues 1–16 of the human Aβ sequence,
and anti-meprin β antibody (1:300), MEP1B (R&D
Systems), for 2 h at 37 °C. For compartment staining
cells were incubated with anti-PDI (abcam, 1:500), anti-
GM130 (BD Transduction Lab, 1:300) or anti EEA1
(Abcam, 1:300) for 2 h at 37 °C. Primary antibody was re-
moved and cells were washed four times with TBS. Re-
spective secondary Alexa-Fluor546 and Alexa-Fluor488
antibodies (Invitrogen) were applied in a 1:500 dilution in
TBS for 1 h at room temperature in the dark. A secondary
antibody control as well as a control with cells that were
not transfected was performed. The coverslips were em-
bedded in ProLong Gold antifade reagent (Invitrogen). Z-
stack images were acquired using a LSM710, AxioObser-
ver confocal laser scanning microscope, Plan-Apochromat
63x/1.40 Oil DIC M27, using ZEN 2008 software (Carl
Zeiss). A representative layer of z-stack is presented in the
results part.
Immunoprecipitation of amyloid β
Supernatants were normalized according to protein con-
tent of cell lysates 24 h post transfection. Immunopre-
cipitation (IP) with magnetic dynabeads M-280 was
performed as described [69]. In brief, 5-fold concen-
trated IP detergent buffer (50 mM HEPES pH 7.4,
150 mM NaCl, 0.5 % (v/v) Nonidet P-40 (NP40), 0.05 %
(w/v) SDS and protease inhibitor cocktail (Roche
Complete) was mixed with supernatant. Magnetic dyna-
beads M-280 containing sheep-anti-mouse-IgG attached
to their surface were precoated with 6E10 antibody
(Covance) or IC16 antibody [25] for murine samples,
both recognizing residues 1–16 of the human Aβ se-
quence, according to manufacturer’s protocol and added
to samples. After incubation for 15 h at 4 °C samples
were washed three times with PBS, 0.1 % BSA and once
with 10 mM Tris–HCl, pH 7.5. Separation from beads
was performed through boiling samples at 95 °C in 25 μl
sample buffer (0.36 M Bis-Tris, 0.16 M Bicine, 1 % (w/v)
SDS, 15 % (w/v) sucrose and 0.0075 % (w/v) bromophe-
nol blue).
Aβ separation with 8 M Urea SDS-Gel and Western Blot
Separation of immunoprecipitated Aβ peptides was per-
formed with 0.75 mm polyacrylamide 8 M urea SDS-
gels as described [70]. To achieve a better separation of
Aβ peptides varying in length of only one to few amino
acids a final concentration of 0.3 M H2SO4 was used for
separation gels. The peptides were transferred to an
Immobilion-P PVDF membrane via semi-dry Western
Blotting (Biorad) at 47 mA/gel for 45 min. Membranes
were boiled for 3 min in PBS and afterwards blocked in
5 % nonfat-dry milk in TBST for 30 min. 6E10 antibody
(Covance, 1:1000 in TBST) or IC16 antibody was used
for overnight immunostaining. After washing in TBST
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the membrane was incubated in secondary anti-mouse
antibody (1:1000 in TBST) for 1 h.
Western Blotting, Quantification and statistical analysis
Samples were eluted in SDS sample buffer and boiled at
95 °C. Total lysates and immunoprecipitates were then
separated on 4-12 % NuPage (Novex, Invitrogen) gradi-
ent gels and transferred onto nitrocellulose membranes
or, for Aβ separation, on Immobilion-P PVDF mem-
branes after activation in methanol. After incubation
with appropriate primary and secondary antibodies, im-
munoreactive bands were visualized using an ECL en-
hanced chemiluminescence system (Millipore). Western
blots were quantified by densitometry using ImageJ 1.44.
All graphs and statistical analyses were prepared using
GraphPad Prism 4 software (GraphPad, La Jolla, CA,
USA).
Biotinylation
HEK-293 T cells were either transiently co-transfected
with human myc-tagged APP695wt-pLHCX or
APPΔNPxY-pLHCX and meprin β-pLBXC or with the
empty vector alone and grown on 10 cm dishes to 90 %
confluency. Biotinylation was performed as previously
described [71]. In brief, cell surface proteins were bio-
tinylated with 0.5 mg/ml Sulfo-NHS-LC-LC-Biotin
(Pierce) in ice-cold PBS at 4 °C for 40 min. Cells were
washed four times with ice-cold PBS containing 50 mM
NH4Cl to quench unconjugated biotin and lysed in NP-
40 buffer. Equal amounts of proteins were incubated
with NeutrAvidin agarose resin (Pierce) at 4 °C over-
night. Biotinylated proteins were recovered by boiling in
2 x SDS sample buffer for 5 min and separated on 4-
12 % NuPage.
Thioflavin T Binding Assay
Synthetic human Aβ1-40 and Aβ2-40 peptides were pro-
cured from VCPBio Lab. Lyophilized peptides were solu-
bilized in 10 mM NaOH to a final peptide concentration
of 230 μM, sonicated for 5 min in water bath (Brandelin
Sonopuls) and stored at −80 °C until further use. Thio-
flavin T (ThT) binding assay was performed as described
previously [72]. Briefly, Aβ1-40 or Aβ2-40 stock solution
(230 μM) was mixed with 50 mM of sodium phosphate
buffer (pH 7.4, 50 mM NaCl, 20 μM ThT and 0.01 % so-
dium azide) to final Aβ concentration of 50 μM. Aggre-
gation kinetic measurements were carried out using a
Varian Cary Eclipse fluorescence spectrophotomer. Sam-
ples were incubated at 37 °C with stirring. The ThT
fluorescence was measured every 5 min for 25 h using
excitation and emission wavelengths of 446 nm and
482 nm, with a slit width of 5 nm respectively. The sam-
ples were analyzed in duplicates in each measurement.
The values in the graph represents the means from 3 in-
dependent measurements (n = 6).
In vitro seeding
For seeding experiments, the previously aggregated Aβ2-
40 peptide solutions were sonicated for 5 min in a water
bath and 5 % (in volume and peptide concentration) ali-
quots of them were added to the fresh Aβ1-40 sample
just prior to incubation at the amyloidogenic condition.
The seeded aggregation of Aβ1-40 was then followed by
ThT fluorescence measurement as described above. The
samples were analyzed in duplicates. The values in graph
represents the means from 2 independent measurements
(n = 4).
HPLC analysis
Synthetic APP peptides (SEVKMDA376EFRH or
SEVKMDT376EFRH respectively) were incubated with 15
nM recombinant human meprin β in 20 mM HEPES for
different time intervals at 37 °C. Recombinant meprin β
has been produced as previously described [73]. The reac-
tion was stopped with 0.1 % TFA/H2O. Afterwards, re-
verse phase HPLC was performed using a gradient from
2 % acetonitrile/ 0.1 % TFA up to 60 % acetonitrile/ 0.1 %
TFA in 38 min. All peak fractions were collected and ana-
lyzed via MALDI MS.
Additional files
Additional file 1: Figure S1. Antibodies 192wt and 7a6 only detect
sAPP in brain soluble fractions of wildtype mice. To test the specificity of
the antibodies 7A6 and 192wt we compared brain soluble fractions of
wildtype and APP ko mice. Here, we could show that by using the
corresponding antibodies both sAPPα and sAPPβ are detectable in brain
soluble fractions of wildtype, but are lacking in those of APP ko. Since
APLP2 can also be detected in APP ko brain membrane fractions, we
show that the knock-out is restricted to APP and does not involve other
members of the APP family. (PDF 646 kb)
Additional file 2: Figure S2. ADAM10 protein levels are not altered in
Mep1b−/− animals. To exclude that the lack of meprin β has any effect
on ADAM10 levels, which could affect sAPP levels, we analyzed lysates of
whole brains from 16 week old Mep1b−/− and wt animals via SDS-PAGE.
By using a C-terminal polyclonal ADAM10 antibody (pineda) we detected
neither a difference on levels of mature ADAM10 nor on levels of the pro
form proADAM10. Therefore, we suggest that, when meprin β is lacking,
the increase of sAPPα levels is indeed a result of higher substrate availabil-
ity for ADAM10 which is independent on a lacking ADAM10/meprin β
interaction. (PDF 566 kb)
Additional file 3: Figure S3. APP and meprin β colocalize in the
secretory pathway and at the cell surface. HEK cells were co-transfected
with APP-GFP and meprin β-dsRed. Both proteins predominantly colocal-
ize in the cis-golgi compartment. Colocalization in early endosomes was
hardly detectable. (PDF 890 kb)
Additional file 4: Figure S4. Meprin β prefers cleavage of wt APP
compared to APP A673T. 15 nM recombinant meprin β was incubated
with synthetic APP peptides for different time intervals. HPLC analysis
showed that processing kinetics of APP A376T (F-J) were decreased
compared to wt APP (A-E). Occurring peaks with smaller retention times
were identified as cleavage products by MALDI MS. Peak intensity has
been measured at 214 nm. (PDF 1715 kb)
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Additional file 5: Figure S5. APP A673T mutation protects from meprin
β mediated cleavage. HEK-293 T cells were transiently transfected with
APPwt or APP A673T mutant and co-transfected with the empty vector or
meprin β. 24 h post transfection supernatants were immunoprecipitated
using Dynabeads conjugated with a 6E10 anti-Aβ antibody, subsequently
separated on an 8 M urea gel and probed with 1E8 anti-Aβ1-x/2-x (A). The
blot was reprobed with 6E10 anti-Aβ antibody. All samples were run on one
gel but rearranged for better presentation. (B) We could exclude a phos-
phorylation at the substituted threonine that causes a shift of Aβ2-40 by de-
phosphorylating with λ-phosphatase (New England Biolabs) after the last
washing step of the immunoprecipitation. Samples were separated on an
8 M urea gel and probed with 6E10 anti-Aβ antibody that showed no
change with or without phosphatase treatment (C). (PDF 936 kb)
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